ERYTECH's Lead AML Drug Flunks Phase II Test Post author:Sam Post published:December 7, 2017 Post category:BioPharma The study enrolled a total of 123 patients at 30 European sites. Source: BioSpace You Might Also Like Auris Medical Fails Again in Phase III Trial March 13, 2018 Roche Launches The Cobas EGFR Mutation Test V2 For Use With Either Plasma Or Tumor Tissue Samples March 13, 2017 Tax Reform Could Lead to Spike in Biopharma M&A Activity February 22, 2018
Roche Launches The Cobas EGFR Mutation Test V2 For Use With Either Plasma Or Tumor Tissue Samples March 13, 2017
